The 6 most recent market catalysts affecting $AGMB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Agomab Says Phase 1 Data In 10 IPF Patients Show Favorable Safety, Target Engagement For Inhaled AGMB-447; Submits CTA For 120-Patient Phase 2 INSPIRIA Study, Targets Start In H2 2026
This headline is a significant corporate catalyst for Agomab. Positive Phase 1 data, especially with favorable safety and target engagement, de-risks the drug candidate AGMB-447 to…
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 65
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
The filing announces new analyst coverage for five companies: Agomab Therapeutics (AGMB), Jersey Mike's Subs (JMKE), Apnimed Inc (APMD), JBT Marel Corp (JBTM), and Kodiak AI Inc (K…
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 65
Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60
Piper Sandler analyst Yasmeen Rahimi has initiated coverage on AgomAb Therapeutics (AGMB) with an 'Overweight' rating and a $60 price target. This is a significant event for the co…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 55
Cantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage on AgomAb Therapeutics (AGMB) with an Overweight rating. This is a positive development for AgomAb as new analyst co…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
AgomAb Therapeutics H1 EPS $(0.93)
AgomAb Therapeutics (AGMB) has announced its quarterly earnings, reporting a loss of $(0.93) per share. This is a critical piece of information for investors as it directly reflect…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 65
B. Riley Securities Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $34
B. Riley Securities analyst William Woods has initiated coverage on AgomAb Therapeutics (AGMB) with a 'Buy' rating and a $34 price target. This event is significant for AGMB as it …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.